VivoSeq
Other

Otomycosis

8

Pipeline Programs

2

Active Trials

3

Companies Involved

Otomycosis is an early-stage landscape with 8 programs across 3 companies. The most active players are Bayer, Cadence Pharmaceuticals, Novartis. 3 programs are in Phase 3.

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Trial Status

12

clinical trials

Completed9 · 75%
Not yet recruiting1 · 8%
Recruiting1 · 8%
Unknown status1 · 8%

Trial Activity

12 trials

Terbinafine Hydrochloride for the Treatment of Otomycosis
Not yet recruiting··N/A·NCT07152327·50 enrolled
SVT-15652 Otic Solution for the Treatment of Otomycosis.
Completed·SSalvat·Phase 3·NCT03686397·194 enrolled
SVT-15652 Otic Solution for the Treatment of Otomycosis
Completed·SSalvat·Phase 3·NCT03686384·217 enrolled
Antifungal Potential of Moringa Olifera Against Otomycosis
Completed··Phase 1·NCT04768829·10 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)